** Shares of British consumer healthcare group Haleon HLN.L up 2.4% at 368.9p
** Stock among the top gainers on FTSE 100 index .FTSE which is up 13.39% YTD
** Goldman Sachs upgrades co's rating to "Buy" from "Neutral"; raises PT to 440p from 415p
** Brokerage says, beyond FY25 we expect HLN to deliver about 5% organic sales growth per annum on average, led by continued momentum in Oral Health
** Adds, into FY26, expect a return to growth in North America, on improved inventory dynamics and innovation
** 11 of the 18 analysts covering the stock have a "Buy" or higher rating, 6 have "Hold", while 1 rates it at "Sell"; median PT is 430p- data compiled by LSEG
** Including session's losses, stock down ~2% YTD
(Reporting by Ankita Bora in Bengaluru)
((Ankita.Bora@thomsonreuters.com))